Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu

Abstract

The emergence of new classes of glucose-lowering drugs that can further reduce cardiovascular risk (CVR) have fundamentally changed the approach to the management of patients with type 2 diabetes mellitus. The most significant changes concerned the strategy of choosing glucose-lowering therapy with a change in priorities from the glycemia level to CVR, which plays a key role in choosing a class of antidiabetic drugs. At the same time, the mechanisms responsible for lowering CVR remain largely unclear. Of undoubted interest is the study of effects of a new glucagon-like peptide-1 receptor agonist, Semaglutide, on the preclinical stage of diastolic dysfunction. The article presents a clinical case of the use of Semaglutide in a patient with arterial hypertension and type 2 diabetes mellitus.

Keywords

• diabetes mellitus
• antidiabetic drugs
• semaglutide